Compare FUND & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUND | CABA |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.8M | 339.1M |
| IPO Year | N/A | 2019 |
| Metric | FUND | CABA |
|---|---|---|
| Price | $9.82 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 15.3K | ★ 4.9M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ 0.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.97 | $1.18 |
| 52 Week High | $10.99 | $4.23 |
| Indicator | FUND | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 41.97 |
| Support Level | $9.87 | N/A |
| Resistance Level | $10.08 | $1.63 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 56.36 | 63.33 |
Sprott Focus Trust Inc is a diversified closed-end investment company. Its primary investment objective is long-term capital growth. To achieve its objective, the Fund may invest its assets in equity securities and in direct obligations of the U.S. Government or its agencies and in the non-convertible preferred stocks & debt securities of domestic and foreign companies. It invests in various sectors, of which Materials, Financials, Energy, Information technology sector account for the majority weightage.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.